

# Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/126390/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Ponsford, Mark J., Pecoraro, Antonio and Jolles, Stephen 2019. Clozapine-associated secondary antibody deficiency. *Current Opinion in Allergy and Clinical Immunology* 19 (6) , pp. 553-562. 10.1097/ACI.0000000000000592  
file

Publishers page: <http://dx.doi.org/10.1097/ACI.0000000000000592>  
<<http://dx.doi.org/10.1097/ACI.0000000000000592>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# Current Opinion in Allergy & Clinical Immunology

## Clozapine associated secondary antibody deficiency

--Manuscript Draft--

<b>Manuscript Number:</b>	ACI190611R1
<b>Full Title:</b>	Clozapine associated secondary antibody deficiency
<b>Article Type:</b>	Review Article
<b>Corresponding Author:</b>	Mark James Ponsford Immunodeficiency Centre for Wales; Tenovus Institute, Cardiff University Cardiff, UNITED KINGDOM
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Immunodeficiency Centre for Wales; Tenovus Institute, Cardiff University
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Mark James Ponsford
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Mark James Ponsford
	Antonio Pecoraro
	Stephen Jolles
<b>Order of Authors Secondary Information:</b>	

# Clozapine associated secondary antibody deficiency

Mark J Ponsford<sup>1,2</sup>, Antonio Pecoraro<sup>1,3</sup> and Stephen Jolles<sup>1</sup>

<sup>1</sup>Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK

<sup>2</sup>Division of Infection & Immunity, Tenovus Institute, Cardiff University, UK

<sup>3</sup>Department of Translational Medical Sciences, Allergy and Clinical Immunology, Center for Basic and Clinical Immunology Research, University of Naples Federico II, Naples, Italy.

**Corresponding Author:** Mark Ponsford ([ponsfordm@cardiff.ac.uk](mailto:ponsfordm@cardiff.ac.uk))

## Abstract

**Purpose of review:** Clozapine has recently been described as a novel cause of secondary antibody deficiency (SAD), associated with long-term therapy. Here we critically review the evidence linking clozapine-use to an increased infection risk, describe immunological alterations, and discuss potential mechanisms.

**Findings:** Individuals with schizophrenia are at 2-5 times more likely to develop pneumonia than the general population, in particular when receiving clozapine. Delayed-onset distinguishes clozapine-associated hypogammaglobulinaemia from agranulocytosis or neutropenia that occur at lesser frequency. Biomarker searches in treatment-resistant schizophrenia highlight an immune signature associated with long-term clozapine use. This includes reduction in class-switched memory B-cells, echoing common variable immunodeficiency. Recent identification of a role for dopamine in T follicular helper – B cell interactions may inform future clinical studies.

**Summary:** The detrimental impact of the increased infection risk associated with clozapine necessitates a re-evaluation of the current monitoring strategies as well as further studies to better understand the underlying mechanisms of SAD in this setting. Based on available evidence, we suggest simple modifications to clozapine monitoring including integration of routine vaccination, smoking cessation, and assessment of humoral immunity. Further studies are required to understand the role of clozapine in neuroinflammation as well as potentially other autoantibody mediated diseases.

**Keywords:** Clozapine, Hypogammaglobulinaemia, Secondary Antibody Deficiency (SAD), Monitoring, Immunoglobulin Replacement Therapy (IgRT).

**Abbreviations:**

ANC	Absolute Neutrophil Count
CSMB	Class-Switched Memory B-cell
CVID	Common Variable Immunodeficiency
DRD	Dopamine Receptor
HBV	Hepatitis B Virus
IgRT	Immunoglobulin Replacement Therapy
NMDA-R	N-Methyl-d-Aspartate Receptor
REMS	Risk Evaluation and Mitigation Strategy
SAD	Secondary Antibody Deficiency
SMI	Severe Mental Illness
SMR	Standardised Mortality Ratio
TFH	T-Follicular Helper
TRS	Treatment Resistant Schizophrenia

**Introduction**

Major global causes of secondary immunodeficiency include malnutrition, HIV, and malaria. In this review we focus on secondary antibody deficiency (SAD) and in particular the novel association of clozapine with SAD. The field of SAD comprises a heterogeneous and expanding group of clinical conditions characterized by a persistent impairment of antibody production due to a wide range of diseases and drugs. The growth in SAD is to a large extent driven by improvements in the therapies and their wider use to treat autoimmunity, inflammation, transplant rejection and malignancy, especially by agents targeting B cells (1). The mechanism(s) of action of the majority of these drugs is immunosuppressive while in contrast clozapine, a dibenzodiazepine atypical antipsychotic, used in treatment resistant schizophrenia (TRS) does not at first glance fall into this category. Indeed, the association of clozapine with SAD was serendipitously discovered as part of population-based screening for antibody deficiency using calculated globulin (2-5).

Clozapine is an important global medication and is one of the World Health Organisation (WHO) essential medicines. It represents one of only two major therapeutic advances in the treatment of schizophrenia in over half a century (chlorpromazine in 1950 and clozapine in 1958) and remains the gold standard therapy for TRS (6). Schizophrenia affects around 1% of the population with 30% of cases being treatment resistant. It has superior efficacy over other antipsychotics in reducing both positive and negative symptoms and is effective in approximately 60% of previously treatment

refractive patients with a significant reduction in suicide risk (7, 8). Clozapine can cause serious adverse effects including agranulocytosis (cumulative incidence 0.8%) (9, 10); necessitating intensive centralised registry-based monitoring systems to support its safe use.

In 2015 in the United States, the Federal Drug Administration (FDA) merged and replaced the six existing clozapine registries combining data from over 50,000 prescribers, 28,000 pharmacies, and 90,000 patients records into a single shared registry for all clozapine products, the Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program ([www.clozapinerems.com](http://www.clozapinerems.com)). Blood testing of the absolute neutrophil count (ANC) is initially required weekly in order to receive ongoing clozapine therapy. Patients with schizophrenia are a vulnerable group with a number of independent risk factors for infection in addition to the potential risk of neutropenia.

The recognition of SAD in this context is important not only because patients receiving long-term clozapine form a large and vulnerable group but also to prevent potential life-threatening infections and irreversible organ damage, such as bronchiectasis. Early detection allows potential changes in monitoring, further immunological assessment or the initiation of therapies to reduce the risks of infection such as vaccination, antibiotics or in selected cases immunoglobulin replacement therapy (IgRT) (11).

We will review the evidence supporting an increase in infections, in particular pneumonia, in patients taking clozapine, the association with SAD and potential mechanisms. In addition, we describe the immunological and clinical features and management of clozapine related antibody deficiency and propose an amendment to the current clozapine REMS monitoring schemes to include testing for SAD.

### Infectious Risk and antibody deficiency in Clozapine-treated patients

Patients with schizophrenia have a 10-20 year reduction of life expectancy compared to the general population (12) with a consistent contribution toward this reduction due to a high risk of respiratory infection (**Table 1**). Patients with chronic psychosis are known to be at greater risk of infection though factors such as elevated smoking rates, metabolic disorders, dental caries and poorer integration with community health providers (13-17). In a recent study, assessing mortality in people with severe mental illness (SMI), the standardised mortality ratio (SMR) was 2.6 higher compared to the general population. Schizophrenia patients had the highest SMR of all, with 3.8 times the number of deaths observed compared to that expected based on the age- and sex-specific rates for the general population (18). Interestingly, 17.8% of deaths were attributable to respiratory disease with mortality for pneumonia 3.8-fold higher compared to the general population, with a SMR of 10.7 in subjects younger than 45 years. Consistent with this and using a similar retrospective approach, the overall incidence of pleural empyema was found to be 2.44-fold greater in schizophrenia than the general population (19). Increasing evidence has highlighted clozapine as the antipsychotic drug most strongly associated with pneumonia risk (20-24). Current users of clozapine alone were twice as likely to develop pneumonia, and use of clozapine combined with other antipsychotics (olanzapine, quetiapine, zotepine, risperidone, or amisulpride) was associated with even greater risk (25). Moreover, although all of the antipsychotics with the exception of amisulpride were significantly associated with increased risk of pneumonia in the first 30 days of use, clozapine had the highest risk-increase both in this interval and long term (25). In keeping with this data, a higher use of antibiotics compared to clozapine-naïve schizophrenia control patients was described in a cohort study including clozapine-treated patients drawn from Danish Central Psychiatric Research Registry (26). It is important to consider the limitations of epidemiological studies to date; for instance, analysis of both the Danish (26) and Taiwanese Registries (19, 25) lacked information on smoking, drinking, nutrition, and social-deprivation status. Socio-economic drift is well-recognised in association with schizophrenia (8) and is plausibly exaggerated in treatment-resistant patients.

In testament to the efficacy of clozapine in the treatment of schizophrenia, a systematic review including 24 studies reported lower mortality rate ratios in patients continuously treated with clozapine compared

to other antipsychotics (27). This finding could reflect the effectiveness of clozapine in increasing the overall level of function, thus leading to the improvement in a number of risk factors linked to lifestyle, cardiovascular disease and reduction in suicide rates (27, 28). However, as this systematic review did not stratify mortality rate ratios based on the cause of death it was not possible to analyse data on the impact of respiratory infections in clozapine-treated patients. Overall, this suggests that reducing infection-related mortality could further enhance clozapine's efficacy.

The relationship between infection, clozapine use, and adverse events are likely to be complex and multi-factorial. Various mechanisms for the increase in infectious risk in clozapine-treated patients have been suggested including smoking, sedation, agranulocytosis, diabetes, alcohol intake, illicit drug use, poor diet and physical inactivity, sialorrhoea, aspiration and, most recently, antibody deficiency (29, 30). The impact of clozapine on antibody deficiency was investigated in a cross-sectional case-control study comparing immunological and clinical features of schizophrenia patients taking either clozapine or other antipsychotics (5). Clozapine-treated patients showed a significant reduction of all three immunoglobulin classes (IgG, IgA and IgM) compared to clozapine-naïve group. In particular, 8.5% of clozapine-treated patients versus 1% of controls had IgG serum levels below the lower limit of the reference range (6.0 g/l); 13.8% of clozapine-treated versus no controls had low IgA levels (<0.80 g/L); and 34% of clozapine-treated versus 15.3% of control group had low IgM levels (<0.50 g/L). Interestingly, a significant association was found between clozapine treatment duration and the degree of reduction in IgG serum levels, with an annual decline of serum IgG by 0.15 g/L, thus suggesting a cumulative effect of clozapine on antibody production (**Figure 1**). This was despite identification and exclusion of possible secondary causes of hypogammaglobulinaemia with additional linear regression analysis to control for possible effect of diagnoses (e.g. asthma or chronic obstructive pulmonary disorder) associated with use of medications with potential immunosuppressive effects (e.g. glucocorticoids) not documented in available psychiatric or electronic healthcare records. In addition, although no differences in levels of specific IgG against haemophilus influenzae B, pneumococcus, and tetanus were observed between the two study-groups, clozapine-treated patients had a significant reduction of pneumococcal-specific IgA and IgM, perhaps reflecting the observed greater relative



reductions in total IgA and IgM levels. Immunological abnormalities were mirrored by the clinical history: clozapine-receiving patients had higher antibiotic use, with 5.3% patients reporting more than five antibiotic courses per year versus 1% in clozapine-naïve group. Taken together the data suggest both a quantitative and qualitative impairment of antibody production associated with clozapine accompanied by an increase in infection susceptibility.

#### Immunological alterations and possible pathogenetic mechanisms

Disturbances of innate immunity associated with clozapine are well described and include transient fever and eosinophilia with a small proportion (<1%) developing neutropenia or agranulocytosis (31-35). Of note, clozapine-induced fever characteristically appears around 10-14 days following initiation, thus might erroneously contribute to the early spike in pneumonia detection rates discussed above (25). Here we focus on adaptive immune disturbances associated with clozapine therapy.

To date, only one study has been reported using multi-parameter flow cytometry to compare TRS patients with healthy volunteers (36). The observed differences include a shift towards naïve B-cell populations, with reduction in plasmablast (CD3<sup>+</sup>CD19<sup>+</sup>IgD<sup>-</sup>CD20<sup>+</sup>CD38<sup>+</sup>) and class-switched memory B (CSMB; CD3<sup>+</sup>CD19<sup>+</sup>IgD<sup>-</sup>CD27<sup>+</sup>) populations. Importantly, 17 of the 18 TRS patients tested had received clozapine therapy with a mean duration of 18 years. Thus, this search for biomarkers of TRS potentially highlights a distinctive immunophenotype of long-term clozapine therapy. Reduced CSMB populations are predictive of immunoglobulin replacement requirement in secondary hypogammaglobulinemia (37). This is in keeping with our initial report (5), and we have independently noted marked a reduction in class-switched memory B-cell populations and plasmablast frequencies among clozapine-treated patients referred clinically based on calculated globulin screening (*manuscript in submission*). Within our cohort of patients requiring immunoglobulin replacement therapy (IgRT) for hypogammaglobulinemia and infection, 7 patients with a diagnosis of schizophrenia of which 6 have a history of clozapine therapy. This raises diagnostic challenges as the constellation of hypogammaglobulinemia, infection susceptibility, and low CSMB, are core defining and diagnostic features of common variable immunodeficiency (CVID) (38, 39). We are currently conducting a survey



of Immunodeficiency Centres to define immunological phenotype in clozapine-treated patients across the UK.

Immunophenotyping also revealed heightened expression of DRD3 on peripheral HLA-DR<sup>+</sup> memory T- and regulatory T-cells in clozapine-treated patients (36). Interplay between neuronal and immune systems has long been recognised (40) and has led to novel therapeutic avenues (41-43). Recently, Papa et al have identified dopamine synthesis occurs within T-follicular helper cells (TFH) of the germinal centre (44). Dopamine release from TFH granule stores is triggered by cognate interaction with B-cells. This acts on the B-cell to stimulate rapid deployment of pre-formed ICOS-ligand to the cell surface, supporting rapid co-stimulation and resulting in CD40L upregulation on the TFH cell (44). Thus, dopamine signalling contributes to a feedforward co-stimulatory loop facilitating T-B cell interactions (**Figure 2**). Dopamine synthesis is not detectable within murine T-cells, suggesting this mechanism has arisen later in evolution. Therefore, computational modelling, instead of conventional murine studies, have been used to predict this mechanism significantly enhances germinal centre output but has little impact on affinity maturation (44).

Could antagonism of germinal centre dopaminergic signalling by antipsychotics underlie clozapine-associated hypogammaglobulinaemia? Whilst certainly an attractive explanation, Papa et al found DRD1 to be the dominant receptor type expressed by human tonsillar B-cells. Based on receptor binding affinities (45), this would predict a class effect for antipsychotics over a clozapine-specific mechanism. Indeed, both haloperidol and a DRD1-specific antagonist were able to block ICOS-L upregulation *in vitro* (44). Nevertheless, previous studies of human B cells have reported frequent expression of both DRD1 and DRD2 (46), and differences between B-cells within blood, lymphoid, and tonsillar tissue are well recognised (47). Extrapolation from these insights is also complicated by changing patterns of dopamine receptor expression following antipsychotic exposure (48). Despite such limitations, this work directly raises clinically relevant questions. Do individuals receiving antipsychotics differ in their ability to mount and sustain a response to vaccination from antipsychotic-naïve individuals? How do different antipsychotics vary in their impact?

We previously demonstrated reduction in serum IgM levels relative to the normal adult range level, and low concentrations of specific IgG to frequently encountered vaccinations, are common across anti-psychotic treated individuals with schizophrenia (5). These results are difficult to interpret in isolation however, as access and uptake of vaccinations is often lower than for those with serious mental illness (49). Remarkably, despite intense interest in the role of early-life infection in the aetiology of psychosis, and convergent evidence indicating an elevated risk of pneumococcal disease (19), few large-scale studies have considered this issue to date. An Ovid Medline Search conducted 28<sup>th</sup> June 2019 using the terms “vaccine OR vaccination” AND “schizophrenia OR psychosis” identified only one major case series in which 175 institutionalised psychiatric patients received Hepatitis B virus (HBV) vaccination. This concluded vaccine response rates were significantly lower than expected for healthy individuals (50). A subsequent case-control study of 415 Chinese schizophrenia patients also found a greater rate of HBV infection in those receiving clozapine, even in those who had received routine immunization (51). Historical studies containing small numbers of patients showed mixed results for vaccination responses (52, 53).

#### Neuroinflammation and immunosuppressive effects of clozapine: two sides of the same coin?

Recognition of anti-neuronal antibodies underlying acute psychosis provides the clearest evidence for the role of autoimmunity in psychiatric disease (54). Antibodies to N-methyl-d-aspartate receptor (NMDA-R) are detectable in approximately 3% of patients with first-episode psychosis, when tested within 6 weeks of commencing antipsychotics (54). Early diagnosis directs treatments to remove autoantibodies and halt production to induce remission (55). It has been suggested TRS may represent an enriched patient cohort with respect to the presence of anti-neuronal antibodies (56). A smaller study identified anti-NMDA-R antibodies in 3 of 43 patients (7%) with chronic treatment-resistance psychosis (57). Intriguingly, in 2 cases, treatment with clozapine resulted in both symptomatic remission and resolution or reduction of autoantibody-titres, whilst the 3rd patient elected to remain on quetiapine with persistence of symptoms (57). Recent insights suggest ongoing germinal centre reactions are essential for anti-NMDA-R autoantibody production (58). Further studies to assess the ability of clozapine to influence this are suggested, for instance utilising recently developed murine models (59).

Based on current auto-antibody prevalence information however, it seems unlikely that an effect targeting anti-neuronal antibodies alone underlies clozapine's superior efficacy.

Evidence of neuroinflammation in the pathophysiology of schizophrenia is growing. Microglial activation is observed in patients with schizophrenia and those at ultra-high risk of psychosis (60). Similarly, induction of neuro-inflammation by administration of a viral mimetic (polyI:C) leads to microglial activation and progressive cognitive impairment in rodents – an effect reversed by clozapine (61). Wider models of neuroinflammation support clozapine's efficacy in amyloid-plaque related neuroinflammation (62) and highlight its superiority to other antipsychotics in ameliorating experimentally induced encephalitis (63). These illuminate potential mechanisms including AMPK-activation (62) and induction of autophagy (64, 65). Autophagy is a key homeostatic process balancing synthesis, degradation/detoxification, and recycling of cellular components (66). Whilst a universal cellular process, autophagy plays a non-redundant role in B-cell development and homeostasis (65, 67), inflammasome activity (68), and appears dysregulated in schizophrenia (69): highlighting it as an important avenue for future research linking clozapine's therapeutic and adverse effects.

#### Management of Clozapine associated antibody deficiency

The nature, timing, and incidence of neutropenia and agranulocytosis have shaped clozapine risk monitoring programmes internationally. Within the first 6 months of clozapine's introduction to Finland, 17 patients developed blood dyscrasias including 8 fatal cases of agranulocytosis due delayed recognition and secondary infection. Now almost 3 decades since its re-introduction, the “no blood, no drug” policy is well established with emphasis on the initiation period (70). Recent changes to the US clozapine REMS programme support widening access and reduced monitoring intensity requirement for clozapine. Currently, requirements are for a *weekly* absolute neutrophil count assessment from initiation to 6 months, every 2 weeks from 6 to 12 months, then monthly after the first 12 months-reflecting a 10-fold decrease in agranulocytosis risk after this point (33, 71). Studies modelling safety and cost have not considered clozapine-associated hypogammaglobulinemia (72, 73). Evidence suggests the magnitude of reduction in immunoglobulins is comparable, if not greater, than that described following long-term combination therapy with rituximab and methotrexate for rheumatoid

arthritis (based on pooled data from the rituximab clinical trials programme) (74). Post-rituximab immunoglobulin reduction is associated with increased risk of recurrent infection (75, 76). Based on these observations, we propose the incorporation of antibody testing within a clozapine risk assessment matrix as infrequent (vs rare) but with moderate (vs high) risk of adverse outcome (compared to agranulocytosis). In general for SAD, the likelihood of requiring IgRT is inverse to IgG levels (11). We therefore suggest changes to clinical monitoring (**Figure 3**). This would begin with documentation of a clinical infection history (including e.g. antibiotic course requirements over past 6 months) and establishing a baseline for humoral immunity *early* after psychosis onset. Serum sampling at this time also allows exclusion of treatable autoimmune causes (54). An integrative approach to mental and physical health should also include measures to improve rates of smoking cessation and vaccination to reduce pneumonia and chronic lung disease risk. We suggest seasonal influenza and pneumococcal vaccination protocols as per national guidance for “at risk” populations (77, 78). Given an increased risk of vaccine preventable hepatitis in this often institutionalized population group (50, 51), we also suggest HBV vaccination with subsequent response evaluation. Our experience of clozapine-associated hypogammaglobulinemia patients supports a stepwise approach to management including consideration of standby antibiotics and regular prophylaxis depending on the frequency and severity of infections. If a significant infection burden remains despite prophylactic antibiotics on a background of hypogammaglobulinaemia and impaired vaccine responses, IgRT should be considered.

Following clozapine withdrawal, we have observed a slow recovery of immunoglobulin levels but rapid return of schizophrenic symptoms - suggesting a separation of mechanism. In practice, close liaison with the patient, psychiatry and immunology teams supports individualised therapy. Immunoglobulin replacement therapy to reduce infection frequency is feasible in this patient population (*manuscript in submission*). Future studies are required to define the health economic impact of extending current monitoring to include total and vaccine-specific immunoglobulin assessment, enabling cost consequence analysis of the excess infection-related healthcare burden attributable to clozapine-associated hypogammaglobulinaemia.

## Conclusions

Premature mortality is a feature of this schizophrenia and undermines clozapine's unique therapeutic efficacy. Clozapine-associated secondary antibody deficiency has only recently been described. Humoral dysfunction may contribute the observed sinopulmonary infection related morbidity and mortality. Our understanding of mechanism remains limited. Early recognition and treatment are likely to improve long-term outcome and quality of life of schizophrenia patients by enabling monitoring and interventions to reduce infection susceptibility. We therefore suggest a structured approach to assessment and risk mitigation, including introduction of routine vaccination and antibody testing to routine clinical care. Larger studies are needed to evaluate the impact of dose, concomitant medications and duration and their interaction with genetic and environmental factors (e.g. smoking) on development of antibody deficiency and the overall risk of sinopulmonary and other infection. Mechanistic insights to clozapine's unique therapeutic efficacy promise to reveal new approaches to combating neuroinflammation and potentially inflammation in a wider context.

### *Key Points:*

- Clozapine treatment is associated with a 2-5 fold increase in pneumonia risk for patients with schizophrenia relative to the general population or alternative antipsychotic users.
- Clozapine associated hypogammaglobulinaemia has been recently described as a treatable cause of sinopulmonary infection susceptibility.
- Dopamine signalling contributes to T follicular helper and B-cell interactions within the germinal centre suggesting antipsychotics may impair the adaptive humoral response.
- An integrated approach improving access to healthcare including smoking cessation, access to vaccination, and evaluation of immune functionality beyond neutrophil testing is suggested.


## Acknowledgements

*All authors contributed equally to this article.*

*Financial support and sponsorship:* MP is supported by a Wellcome Trust ISSF3 grant and Welsh Clinical Academic Training Fellowship.

*Conflict of interest:* S.J. has received support from CSL Behring, Shire, Takeda, LFB, Biotest, Binding Site, Sanofi, GSK, UCB Pharma, Grifols, BPL SOBI, Weatherden, Zarodex and Octapharma for projects, advisory boards, meetings, studies, speaker and clinical trials. MP and AP report none.


Figure 1: Effect of duration of non-clozapine antipsychotic (upper) or clozapine (lower) treatment on immunoglobulin IgG levels.



No correlation was seen with serum IgG level and non-clozapine antipsychotic medications ( $P = 0.14$ ) despite a longer duration on therapy. A significant negative correlation of duration of clozapine use (years) was observed with an annual reduction in IgG levels of 0.15 g/L ( $P = 0.03$ ). Straight lines show predicted IgG at different durations of treatment (in years), based on fitted linear models. Shaded regions display pointwise 95% confidence intervals. Dotted lines indicate normal range for IgG 6.0-16g/L. Reproduced with permission from (5).



Figure 2: Dopamine's actions within the germinal centre (based on (44))



1: Antigen presentation by B-cell stimulates dopamine release from T-follicular helper cell

2: Dopamine acts via cell-surface receptors, triggers ICOS trafficking from intracellular stores to the B-cell surface

3: ICOS ligand - ICOS interaction provides co-stimulatory signal for the TFH cell

4: CD40L- CD40 interaction stimulates B-cell survival and differentiation

*Image created by MP using Biorender tool.*

Figure 3: Suggested flowchart for monitoring of humoral immunity during clozapine therapy




Table 1: Mortality and risk of pneumonia in schizophrenia.

Selected cohort studies investigating overall mortality, pneumonia-related mortality, and risk of pneumonia across schizophrenia and specifically clozapine-treated patients. Studies concerning other indications for antipsychotic prescription were excluded. Note studies differ in study design, population analysed, outcome considered and statistical methods, thus limiting comparison of results. SMR = standardized mortality rate; MRR = mortality rate ratio; AHR = adjusted hazard ratio; HR = hazard ratio; OR = odds ratio; RR = relative risk; ARR = adjusted risk ratio.

Study	Year	Outcome	S i
Overall Mortality in Schizophrenia			
John et al. (18)	2018	Overall mortality in schizophrenia compared to general population	
Hayes et al. (17)	2017	Overall mortality in schizophrenia compared to general population	
Pneumonia Risk and Mortality in Schizophrenia			
John et al. (18)	2018	Mortality for pneumonia in schizophrenia compared to general population	
Shen et al (79)	2017	Risk of pleural empyema in patients with Taiwanese patients with schizophrenia relative to matched control group from general population.	
Seminog et al (19)	2013	Rates of pneumococcal pneumonia in England based on linked hospital episode statistics	
Chou et al. (16)	2013	Risk of pneumonia in schizophrenia compared to general population	
		Mortality for pneumonia in schizophrenia compared to general population	
Overall Mortality in Clozapine-treated Schizophrenia			
Vermeulen et al. (27)	2018	Overall mortality in clozapine-treated compared to clozapine-naïve schizophrenia patients	

Tiihonen et al. (28)	2009	Overall mortality in clozapine-treated compared to clozapine-naïve schizophrenia patients	
<b><i>Risk of Pneumonia in Clozapine-treated Schizophrenia</i></b>			
Stoecker et al. (20)	2017	Risk of pneumonia in clozapine-treated compared to general population	
Kuo et al. (25)	2013	Risk of pneumonia in clozapine-treated compared to clozapine-naïve schizophrenia patients	
		Risk of pneumonia in patients treated with clozapine + any other antipsychotic compared to clozapine-naïve schizophrenia patients	
Haddad et al. (24)	2013	Risk of pneumonia in clozapine-treated compared to no-drug-use controls	

## References

1. Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. *Front Immunol.* 2019;10:33.
2. Holding S, Khan S, Sewell WA, Jolles S, Dore PC. Using calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration project. *Annals of Clinical Biochemistry.* 2015;52(3):319-26.
3. Jolles S, Borrell R, Zouwail S, Heaps A, Sharp H, Moody M, et al. Calculated globulin (CG) as a screening test for antibody deficiency. *Clinical and experimental immunology.* 2014;177(3):671-8.  
\* *First identification of clozapine in association with hypogammaglobulinaemia using unbiased screening approach.*
4. Holding S, Jolles S. Current screening approaches for antibody deficiency. *Current Opinion in Allergy and Clinical Immunology.* 2015;15(6):547-55.
5. Ponsford M, Castle D, Tahir T, Robinson R, Wade W, Steven R, et al. Clozapine is associated with secondary antibody deficiency. *The British Journal of Psychiatry.* 2018:1-7.  
\*\* *Cross-sectional case-control study confirming clozapine-specific association with hypogammaglobulinaemia in schizophrenia vs. disease controls. Multivariate linear regression suggests this may be a late effect of therapy.*
6. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. *Hist Psychiatry.* 2007;18(1):39-60.
7. Meltzer HY, Alphas L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry.* 2003;60(1):82-91.
8. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. *Lancet.* 2016;388(10039):86-97.
9. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. *N Engl J Med.* 1993;329(3):162-7.
10. Idanpaan-Heikkilä J, Alhava E, Olkinuora M, Palva I. Letter: Clozapine and agranulocytosis. *Lancet.* 1975;2(7935):611.
11. Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. *Clin Exp Immunol.* 2017;188(3):333-41.  
\* *Practical approach to assessment of infection history and management of antibody deficiency*
12. Laursen TM, Nordentoft M, Mortensen PB. Excess Early Mortality in Schizophrenia. *Annual Review of Clinical Psychology.* 2014;10(1):425-48.
13. Kisely S, Ehrlich C, Kendall E, Lawrence D. Using Avoidable Admissions to Measure Quality of Care for Cardiometabolic and other Physical Comorbidities of Psychiatric Disorders: A Population-Based, Record-Linkage Analysis. *The Canadian Journal of Psychiatry.* 2015;60(11):497-506.

14. Cicala G, Barbieri MA, Spina E, de Leon J. A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. *Expert Review of Clinical Pharmacology*. 2019;12(3):219-34.
15. Toender A, Munk-Olsen T, Vestergaard M, Larsen JT, Suppli NP, Dalton SO, et al. Impact of severe mental illness on cancer stage at diagnosis and subsequent mortality: A population-based register study. *Schizophrenia Research*. 2018;201:62-9.
16. Chou FH-C, Tsai K-Y, Chou Y-M. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: A nine-year follow-up study. *Journal of Psychiatric Research*. 2013;47(4):460-6.
17. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. *The British journal of psychiatry : the journal of mental science*. 2017;211(3):175-81.  
*\* Highlights the growing mortality gap in this vulnerable population to the general population*
18. John A, McGregor J, Jones I, Lee SC, Walters JTR, Owen MJ, et al. Premature mortality among people with severe mental illness — New evidence from linked primary care data. *Schizophrenia Research*. 2018;199:154-62.  
*\*\* Estimated standardised mortality ratios for all-cause and cause-specific mortality in people with severe mental illness drawn from linked primary and secondary care populations compared to the general population*
19. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. *Thorax*. 2013;68(2):171-6.  
*\* Epidemiological support for routine pneumococcal vaccination of this patient group.*
20. Stoecker ZR, George WT, O'Brien JB, Jancik J, Colon E, Rasimas JJ. Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. *International Clinical Psychopharmacology*. 2017;32(3):155-60.
21. Taylor DM D-HP, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. *The British Journal of Psychiatry*. 2009;194(2):165-7.  
*\* Highlights that death is more commonly observed as reason for discontinuation of clozapine than of risperidone, with a significantly raised standardised mortality ratio in clozapine-receiving patients.*
22. Trifio G. Antipsychotic Drug Use and Community-Acquired Pneumonia. *Current infectious disease reports*. 2011;13(3):262-8.
23. Abdelmawla N, Ahmed MI. Clozapine and risk of pneumonia. *British Journal of Psychiatry*. 2009;194(5):468-9.
24. Haddad PM. Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia. *Evidence based mental health*. 2013;16:109.
25. Kuo CJ YS, Liao YT, Chen WJ, Lee WC, Shau WY, Chang YT, Tsai SY, Chen CC. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. *Schizophrenia bulletin*. 2013;39(3):648-57.  
*\*Demonstrates the higher risk of pneumonia associated with second-generation antipsychotics- specifically clozapine as monotherapy or in combination. Risk appears greatest during the first 30-days of therapy but remains elevated even >180 days.*
26. Nielsen J, Foldager L, Meyer JM. Increased use of antibiotics in patients treated with clozapine. *European Neuropsychopharmacology*. 2009;19(7):483-6.
27. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutherland AL, Correll CU, de Haan L. Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years. *Schizophrenia Bulletin*. 2018;45(2):315-29.  
*\*Systematic review and Metanalysis assessing mortality in clozapine-treated patients compared to those receiving other antipsychotics*

28. Tiihonen J, Lönngqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *Lancet*. 2009;374(9690):620-7.  
*\* Clozapine use reduces overall mortality- suggesting risk awareness and mitigation to reduce infectious mortality could further enhance its benefits.*
29. Hung G, Liu H, Yang S, Pan C, Liao Y, Chen C, et al. Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study. *Journal of Clinical Immunology*. 2016;77(1):60-6.
30. Leung J, Hasassri M, Barreto J, Nelson S, Morgan Rr. Characterization of Admission Types in Medically Hospitalized Patients Prescribed Clozapine. *Psychosomatics*. 2017;58(2):164-72.  
*\* Retrospective case series highlighting burden of pneumonia in clozapine treated patients*
31. Chung JP-Y, Chong CS-Y, Chung K-F, Dunn EL-W, Tang OW-N, Chan W-F. The Incidence and Characteristics of Clozapine-Induced Fever in a Local Psychiatric Unit in Hong Kong. *The Canadian Journal of Psychiatry*. 2008;53(12):857-62.
32. Hung Y-P, Wang CS-M, Yen C-N, Chang H-C, Chen PS, Lee IH, et al. Role of cytokine changes in clozapine-induced fever: A cohort prospective study. *Psychiatry and Clinical Neurosciences*. 2017;71(6):395-402.
33. Ingimarsson O, MacCabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. *BMC Psychiatry*. 2016;16(1):441.
34. Schulte PFJ. Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring. *Annals of Pharmacotherapy*. 2006;40(4):683-8.
35. Banov M, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. *Journal of Clinical Psychiatry*. 1993;54(12):466-9.
36. Fernandez-Egea E, Vértés PE, Flint SM, Turner L, Mustafa S, Hatton A, et al. Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia. *PloS one*. 2016;11(5):e0155631-e.  
*\*\* First detailed immunophenotyping of TRS/ clozapine-treated patient cohort to date, highlighting a number of potential immune signatures of clozapine therapy including reduction of CSMB.*
37. McNulty CMG, Joshi AY. Low class switched memory B cells predicts the need for continued need for replacement immunoglobulin therapy post Rituximab use and adequate numeric B cell reconstitution. *Journal of Allergy and Clinical Immunology*. 2018;141(2):AB83.
38. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. *The journal of allergy and clinical immunology In practice*. 2016;4(1):38-59.
39. Warnatz K, Denz A, Dräger R, Braun M, Groth C, Wolff-Vorbeck G, et al. Severe deficiency of switched memory B cells (CD27+IgM-IgD-) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. *Blood*. 2002;99(5):1544-51.
40. Tracey KJ. Reflex control of immunity. *Nat Rev Immunol*. 2009;9(6):418-28.
41. Rana M, Fei-Bloom Y, Son M, La Bella A, Ochani M, Levine YA, et al. Constitutive Vagus Nerve Activation Modulates Immune Suppression in Sepsis Survivors. *Frontiers in Immunology*. 2018;9(2032).
42. Johnston GR, Webster NR. Cytokines and the immunomodulatory function of the vagus nerve. *British Journal of Anaesthesia*. 2009;102(4):453-62.
43. First-in-human study of novel implanted vagus nerve stimulation device to treat rheumatoid arthritis. [press release]. EULAR Madrid Press Release 2019.
44. Papa I, Saliba D, Ponzoni M, Bustamante S, Canete PF, Gonzalez-Figueroa P, et al. TFH-derived dopamine accelerates productive synapses in germinal centres. *Nature*. 2017;547:318.  
*\*\* Novel insights to the mechanistic role of dopamine signalling supporting germinal centre interactions and antibody production.*

45. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Molecular Psychiatry*. 2005;10(1):79-104.
46. Meredith EJ, Holder MJ, Rosén A, Lee AD, Dyer MJS, Barnes NM, et al. Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. *Proc Natl Acad Sci U S A*. 2006;103(36):13485-90.
47. Pérez ME, Billordo LA, Baz P, Fainboim L, Arana E. Human memory B cells isolated from blood and tonsils are functionally distinctive. *Immunology & Cell Biology*. 2014;92(10):882-7.
48. Damask SP, Bovenkerk KA, de la Pena G, Hoversten KM, Peters DB, Valentine AM, et al. Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex. *Molecular Brain Research*. 1996;41(1):241-9.
49. Lord O, Malone D, Mitchell AJ. Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis. *General Hospital Psychiatry*. 2010;32(5):519-43.
50. Russo R, Ciminale M, Ditommaso S, Siliquini R, Zotti C, Moiraghi Ruggerini A. Hepatitis B vaccination in psychiatric patients. *Lancet*. 1994;343(8893):356.  
*\* Schizophrenia is associated with increased risk of hepatitis B, and suggestion of reduced efficacy of vaccination*
51. Wang Y, Yu L, Zhou H, Zhou Z, Yinghui L, Zhen Z, et al. Serologic and molecular characteristics of hepatitis B virus infection in vaccinated schizophrenia patients in China. *Journal of Infection in Developing Countries*. 2016;10(4).
52. Friedman S, Cohen J, Iker H. Antibody Response to Cholera Vaccine: Differences Between Depressed, Schizophrenic, and Normal Subjects. *Archives of General Psychiatry*. 1967;16:312-5.
53. Solomon GF, Rubbo SD, Batchelder E. Secondary immune response to tetanus toxoid in psychiatric patients. *Journal of Psychiatric Research*. 1970;7(3):201-7.
54. Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. *The Lancet Psychiatry*. 2017;4(1):42-8.
55. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol*. 2013;12(2):157-65.
56. Colijn MA, Ismail Z. Clinically Relevant Anti-Neuronal Cell Surface Antibodies in Schizophrenia Spectrum Disorders. *Neuropsychobiology*. 2019;78(2):70-8.
57. Beck K, Lally J, Shergill SS, Bloomfield MAP, MacCabe JH, Gaughran F, et al. Prevalence of serum N-methyl-D-aspartate receptor autoantibodies in refractory psychosis. *The British journal of psychiatry : the journal of mental science*. 2015;206(2):164-5.  
*\* NMDA-receptor autoantibodies are present in chronic psychosis and appear reduced following commencement of clozapine therapy.*
58. Makuch M, Wilson R, Al-Diwani A, Varley J, Kienzler A-K, Taylor J, et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications. *Ann Neurol*. 2018;83(3):553-61.
59. Jones BE, Tovar KR, Goehring A, Okada NJ, Gouaux E, Westbrook GL. Anti-NMDA receptor encephalitis in mice induced by active immunization with conformationally-stabilized holoreceptors. *bioRxiv*. 2018:467902.
60. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, et al. Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [11C]PBR28 PET Brain Imaging Study. *American Journal of Psychiatry*. 2015;173(1):44-52.
61. Ribeiro BMM, do Carmo MRS, Freire RS, Rocha NFM, Borella VCM, de Menezes AT, et al. Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine. *Schizophrenia Research*. 2013;151(1):12-9.



62. Choi Y, Jeong HJ, Liu QF, Oh ST, Koo B-S, Kim Y, et al. Clozapine Improves Memory Impairment and Reduces A $\beta$  Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. *Molecular Neurobiology*. 2017;54(1):450-60.
63. Green LK, Zareie P, Templeton N, Keyzers RA, Connor B, La Flamme AC. Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis. *Multiple sclerosis journal - experimental, translational and clinical*. 2017;3(1):2055217317698724-.
- \* *Clozapine exerts immunomodulatory effects in a model of neuroinflammation.*
64. Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nature Cell Biology*. 2011;13:132.
65. Kim SH, Park S, Yu HS, Ko KH, Park HG, Kim YS. The antipsychotic agent clozapine induces autophagy via the AMPK-ULK1-Beclin1 signaling pathway in the rat frontal cortex. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2018;81:96-104.
66. Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, et al. Molecular definitions of autophagy and related processes. *The EMBO journal*. 2017;36(13):1811-36.
67. Sandoval H, Kodali S, Wang J. Regulation of B cell fate, survival, and function by mitochondria and autophagy. *Mitochondrion*. 2018;41:58-65.
68. Lee PP, Lobato-Márquez D, Pramanik N, Sirianni A, Daza-Cajigal V, Rivers E, et al. Wiskott-Aldrich syndrome protein regulates autophagy and inflammasome activity in innate immune cells. *Nature Communications*. 2017;8(1):1576.
69. Schneider JL, Miller AM, Woesner ME. Autophagy and Schizophrenia: A Closer Look at How Dysregulation of Neuronal Cell Homeostasis Influences the Pathogenesis of Schizophrenia. *Einstein J Biol Med*. 2016;31(1-2):34-9.
70. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing Clozapine-Related Morbidity and Mortality: 5 Years of Experience With the Clozaril National Registry. *Journal of Clinical Psychiatry*. 1998;59 (S3):3-7.
71. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12760 clozapine recipients in the UK and Ireland: Beyond pharmacovigilance. *British Journal of Psychiatry*. 1999;175(6):576-80.
72. Girardin FR, Poncet A, Blondon M, Rollason V, Vernaz N, Chalandon Y. Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. *Lancet Psychiatry*. 2014;1(1):55-62.
73. Girardin FR, Poncet A, Perrier A, Vernaz N, Pletscher M, F Samer C, et al. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. *Pharmacogenomics J*. 2019;19(2):211-8.
- \* *Healthcare economic evaluation approaches based on current low incidence of agranulocytosis and neutropenia argue for a reduction in testing intensity.*
74. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. *Annals of the Rheumatic Diseases*. 2013;72(9):1496-502.
75. Kasavkar G, Kamath S. AB0399 Rituximab treatment and immunoglobulin levels monitoring. *Annals of the Rheumatic Diseases*. 2017;76(Suppl 2):1188-9.
76. Makatsori M, Kiani-Alikhan S, Manson AL, Verma N, Leandro M, Gurugama NP, et al. Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes. *QJM: An International Journal of Medicine*. 2014;107(10):821-8.
77. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. *Clinical Infectious Diseases*. 2013;58(3):e44-e100.
78. England PH. Pneumococcal immunisation information for public health professionals, including updates. *The Green Book*. 2013;Chapter 25.

79. Shen T-C, Chen C-H, Huang Y-J, Lin C-L, Chang T-C, Tu C-Y, et al. Risk of pleural empyema in patients with schizophrenia: a nationwide propensity-matched cohort study in Taiwan. *BMJ Open*. 2018;8(7):e021187.

Response to reviewers: [ACI190611](#)

Thank you for the reviewer's kind and helpful comments

*We have adjusted the text to reflect the limitations of epidemiological studies to date, highlighting social drift as a potential confounding variable accompanying clozapine therapy.*

I look forward to reading the manuscript in press on the immunologic flow cytometry changes in the B cell compartment among clozapine-treated patients.

*-Thank you, this is currently with reviewers.*

The data discussed showed low IgG levels in clozapine treated patients, are there data associating these IgG levels with infection? Do the authors anticipate similar effects to what is noted in antiseizure medications and hypogammaglobulinemia? Is there data correlating IgG levels and infection risk in this population?

*We have added some additional detail concerning this study to stir the reader's interest: Within our cohort of patients requiring immunoglobulin replacement therapy (IgRT) for hypogammaglobulinemia and infection, 7 patients with a diagnosis of schizophrenia of which 6 have a history of clozapine therapy.*

The proposal for Igs/ specific vaccination titers testing in Clozapine treated patients seems reasonable. Would the authors dare discuss the potential opportunity of a cost analysis? Would be a study in and of itself....

*This is in fact part of an active submission. We have amended the text to: include total and vaccine-specific immunoglobulin assessment, enabling cost consequence analysis of the excess infection-related healthcare burden attributable to clozapine-associated hypogammaglobulinaemia.*

Minor changes:

Table 1:

Remove underlined section: " Risk of pleural empyema in patients with Taiwanese patients with schizophrenia relative to matched control group from general population"

*We regret we could not identify an underlined section but would be happy to edit this if it still appears within revised version.*

Figure 2:

Numbers 1, 2, 3 and 4 are missing from the figure


*Thank you, we have updated this in the revised version*


Figure 3:


Is S. Typhi antibody titers a routine analysis recommended for adults with hypogammaglobulinemia? Similarly HIB titers are commonly collected in children, should they also be collected in adults?

*Our centre's practice is to make use of a combination of vaccination responses (including Hib and S typhi), however in light of recent surveys (e.g. UKPIN) we recognise variation in practice exists. This is beyond the scope of this review, and we have amended the Figure to reference Jolles et al: "When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017;188(3):333-41" which provides a more complete discussion.*

Figure 1







**Table 1. Mortality and risk of pneumonia in schizophrenia.**

Cohort studies investigating overall mortality, mortality for pneumonia and risk of pneumonia in all schizophrenia or clozapine-treated patients compared to general population or clozapine-naïve patients. Various studies differ in study design, population analysed, outcome considered and statistical methods, thus limiting comparison of results. SMR = standardized mortality rate; MRR = mortality rate ratio; AHR = adjusted hazard ratio; HR = hazard ratio; OR = odds ratio; RR = relative risk; ARR = adjusted risk ratio.

Study	Year	Outcome	Statistical indicator	Result	95% C.I.
<i>Overall Mortality in Schizophrenia</i>					
John et al. (1)	2018	Overall mortality in schizophrenia compared to general population	SMR	2.9	2.8-3.0
Hayes et al. (2)	2017	Overall mortality in schizophrenia compared to general population	HR	2.08	1.98-2.19
<i>Pneumonia Risk and Mortality in Schizophrenia</i>					
John et al. (1)	2018	Mortality for pneumonia in schizophrenia compared to general population	SMR	3.8	3.5-4.2
Shen et al (3)	2017	Risk of pleural empyema in Taiwanese patients with schizophrenia relative to matched control group from general population	AHR	2.87	2.14 - 3.84



Seminog et al (4)	2013	Rates of pneumococcal pneumonia in England based on linked hospital episode statistics	RR	2.5	1.9-3.2
Chou et al. (5)	2013	Risk of pneumonia in schizophrenia compared to general population	HR	1.77	1.67-1.88
		Mortality for pneumonia in schizophrenia compared to general population	HR	1.39	1.29-1.50
<i>Overall Mortality in Clozapine-treated</i>					
Vermeulen et al. (6)	2018	Overall mortality in clozapine-treated compared to clozapine-naïve schizophrenia patients	MRR	0.56	0.36-0.85
Tiihonen et al. (7)	2009	Overall mortality in clozapine-treated compared to clozapine-naïve schizophrenia patients	AHR	0.74	0.6-0.91
<i>Risk of Pneumonia in Clozapine-treated</i>					
Stoecker et al. (8)	2017	Risk of pneumonia in clozapine-treated compared to general population	OR	4.07	2.25-7.36
Kuo et al. (9)	2013	Risk of pneumonia in clozapine-treated compared to clozapine-naïve schizophrenia patients	ARR	2.01	1.54-2.61
		Risk of pneumonia in patients treated with clozapine + any other antipsychotic compared to clozapine-naïve schizophrenia patients	ARR	4.78	3.68-6.23
Haddad et al. (10)	2013	Risk of pneumonia in clozapine-treated compared to no-drug-use controls	RR	3.18	2.62-3.86

NB EDITORIAL NOTE THE REFERENCES HERE DO NOT MATCH ARTICLE

1. John A, McGregor J, Jones I, Lee SC, Walters JTR, Owen MJ, et al. Premature mortality among people with severe mental illness — New evidence from linked primary care data. *Schizophrenia Research*. 2018;199:154-62.
2. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. *The British journal of psychiatry : the journal of mental science*. 2017;211(3):175-81.
3. Shen T-C, Chen C-H, Huang Y-J, Lin C-L, Chang T-C, Tu C-Y, et al. Risk of pleural empyema in patients with schizophrenia: a nationwide propensity-matched cohort study in Taiwan. *BMJ Open*. 2018;8(7):e021187.
4. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. *Thorax*. 2013;68(2):171-6.
5. Chou FH-C, Tsai K-Y, Chou Y-M. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: A nine-year follow-up study. *Journal of Psychiatric Research*. 2013;47(4):460-6.
6. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutherland AL, Correll CU, de Haan L. Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years. *Schizophrenia Bulletin*. 2018;45(2):315-29.
7. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *Lancet*. 2009;374(9690):620-7.
8. Stoecker ZR, George WT, O'Brien JB, Jancik J, Colon E, Rasimas JJ. Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. *International Clinical Psychopharmacology*. 2017;32(3):155-60.
9. Kuo CJ YS, Liao YT, Chen WJ, Lee WC, Shau WY, Chang YT, Tsai SY, Chen CC. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. *Schizophrenia bulletin*. 2013;39(3):648-57.
10. Haddad PM. Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia. *Evidence based mental health*. 2013;16:109.